The overall goal of the Mitogenic Signaling Networks project is the development of high level statistical and specific physico-chemical models that describe key features of mitogenic signaling networks activated by ErbB receptors and by oncogenic K-ras. Over the past 4 years we have made significant progress in developing models of ErbB family mitogenic signaling networks in a variety of cell types, including statistical and kinetic models describing the effects of increased expression of various ErbB family members. Over the next five years we will extend these models to include mitogenic signaling networks resulting from mutant isoforms of EGFR and K-Ras that are directly associated with poor prognosis in human cancers of the central nervous and respiratory systems. Models will be developed and tested at a variety of scales, including in vitro cell culture systems, murine xenografts, and mouse cancer models. In addition, due to the success of a pilot project funded from our current ICBP, we will extend these models to integrate transcriptional regulatory networks, providing a more global, quantitative model of cellular regulation in response to oncogenic mutation. Since therapeutic resistance is one of the hallmarks of lung and brain tumors driven by mutant EGFR and mutant Ras, in the next phase of this project we will quantify and model signaling and transcriptional network alterations resulting from treatment with a variety of therapeutics, including classical chemotherapeutics, targeted therapeutics, and radiation. The goal of this project is to understand adaptation mechanisms used by tumor cells in developing therapeutic resistance in order to target these adaptive mechanisms to revert resistance. Quantitative models of mitogenic signaling network responses to therapeutics will be applied to human tumors to test their ability to predict responsiveness of human tumors to selected chemotherapeutic agents. This project will facilitate the integration of mitogenic signaling network models with DNA damage response models developed in Project 2, leading to more integrated models of cellular regulatory networks.

Public Health Relevance

EGFR and Ras mutations are prevalent in brain and lung cancers and are correlated with poor patient prognosis. Current therapeutic options have not significantly extended survival rates. We propose to develop quantitative models describing signaling and transcriptional networks activated by these mutant isoforms. Models will be used to identify novel therapeutic targets and adaptive mechanisms associated with therapeutic resistance.

Agency
National Institute of Health (NIH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-10
Application #
8619592
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2014) Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A 111:10773-8
Bell, Eric L; Nagamori, Ippei; Williams, Eric O et al. (2014) SirT1 is required in the male germ cell for differentiation and fecundity in mice. Development 141:3495-504
Arneja, Abhinav; Johnson, Hannah; Gabrovsek, Laura et al. (2014) Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 192:123-35
Krueger, Andrew T; Kroll, Carsten; Sanchez, Edgar et al. (2014) Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions. Angew Chem Int Ed Engl 53:2662-6
Beck, Jon R; Peterson, Laura B; Imperiali, Barbara et al. (2014) Quantification of protein kinase enzymatic activity in unfractionated cell lysates using CSox-based sensors. Curr Protoc Chem Biol 6:135-56
Niepel, Mario; Hafner, Marc; Pace, Emily A et al. (2014) Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol 12:20
Johnson, Hannah; White, Forest M (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13:4581-93
Hemann, Michael T (2014) From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov 4:516-8
Buck, Lorenna D; Inman, S Walker; Rusyn, Ivan et al. (2014) Co-regulation of primary mouse hepatocyte viability and function by oxygen and matrix. Biotechnol Bioeng 111:1018-27
Morton, Stephen W; Lee, Michael J; Deng, Zhou J et al. (2014) A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal 7:ra44

Showing the most recent 10 out of 122 publications